Literature DB >> 23927294

Dosimetric characterization of the GammaClip™ 169Yb low dose rate permanent implant brachytherapy source for the treatment of nonsmall cell lung cancer postwedge resection.

Blake Currier, John J Munro, David C Medich.   

Abstract

PURPOSE: A novel (169)Yb low dose rate permanent implant brachytherapy source, the GammaClip™, was developed by Source Production & Equipment Co. (New Orleans, LA) which is designed similar to a surgical staple while delivering therapeutic radiation. In this report, the brachytherapy source was characterized in terms of "Dose calculation for photon-emitting brachytherapy sources with average energy higher than 50 keV: Report of the AAPM and ESTRO" by Perez-Calatayud et al. [Med. Phys. 39, 2904-2929 (2012)] using the updated AAPM Task Group Report No. 43 formalism.
METHODS: Monte Carlo calculations were performed using Monte Carlo N-Particle 5, version 1.6 in water and air, the in-air photon spectrum filtered to remove photon energies below 10 keV in accordance with TG-43U1 recommendations and previously reviewed (169)Yb energy cutoff levels [D. C. Medich, M. A. Tries, and J. M. Munro, "Monte Carlo characterization of an Ytterbium-169 high dose rate brachytherapy source with analysis of statistical uncertainty," Med. Phys. 33, 163-172 (2006)]. TG-43U1 dosimetric data, including SK, Ḋ(r,θ), Λ, gL(r), F(r, θ), φan(r), and φan were calculated along with their statistical uncertainties. Since the source is not axially symmetric, an additional set of calculations were performed to assess the resulting axial anisotropy.
RESULTS: The brachytherapy source's dose rate constant was calculated to be (1.22±0.03) cGy h(-1) U(-1). The uncertainty in the dose to water calculations, Ḋ(r,θ), was determined to be 2.5%, dominated by the uncertainties in the cross sections. The anisotropy constant, φan, was calculated to be 0.960±0.011 and was obtained by integrating the anisotropy factor between 1 and 10 cm using a weighting factor proportional to r(-2). The radial dose function was calculated at distances between 0.5 and 12 cm, with a maximum value of 1.20 at 5.15±0.03 cm. Radial dose values were fit to a fifth order polynomial and dual exponential regression. Since the source is not axially symmetric, angular Monte Carlo calculations were performed at 1 cm which determined that the maximum azimuthal anisotropy was less than 8%.
CONCLUSIONS: With a higher photon energy, shorter half-life and higher initial dose rate 169Yb is an interesting alternative to 125I for the treatment of nonsmall cell lung cancer.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23927294      PMCID: PMC3732308          DOI: 10.1118/1.4812675

Source DB:  PubMed          Journal:  Med Phys        ISSN: 0094-2405            Impact factor:   4.071


  19 in total

1.  Radial dose distribution, dose to water and dose rate constant for monoenergetic photon point sources from 10 keV to 2 MeV:EGS4 Monte Carlo model calculation.

Authors:  G Luxton; G Jozsef
Journal:  Med Phys       Date:  1999-12       Impact factor: 4.071

2.  An analysis of MCNP cross-sections and tally methods for low-energy photon emitters.

Authors:  John J Demarco; Robert E Wallace; Kirsten Boedeker
Journal:  Phys Med Biol       Date:  2002-04-21       Impact factor: 3.609

3.  Brachytherapy dosimetry of 125I and 103Pd sources using an updated cross section library for the MCNP Monte Carlo transport code.

Authors:  Tim D Bohm; Paul M DeLuca; Larry A DeWerd
Journal:  Med Phys       Date:  2003-04       Impact factor: 4.071

4.  The radial dose function of low-energy brachytherapy seeds in different solid phantoms: comparison between calculations with the EGSnrc and MCNP4C Monte Carlo codes and measurements.

Authors:  B Reniers; F Verhaegen; S Vynckier
Journal:  Phys Med Biol       Date:  2004-04-21       Impact factor: 3.609

5.  Phantom size in brachytherapy source dosimetric studies.

Authors:  J Pérez-Calatayud; D Granero; F Ballester
Journal:  Med Phys       Date:  2004-07       Impact factor: 4.071

6.  Update of AAPM Task Group No. 43 Report: A revised AAPM protocol for brachytherapy dose calculations.

Authors:  Mark J Rivard; Bert M Coursey; Larry A DeWerd; William F Hanson; M Saiful Huq; Geoffrey S Ibbott; Michael G Mitch; Ravinder Nath; Jeffrey F Williamson
Journal:  Med Phys       Date:  2004-03       Impact factor: 4.071

7.  Ytterbium-169: calculated physical properties of a new radiation source for brachytherapy.

Authors:  D L Mason; J J Battista; R B Barnett; A T Porter
Journal:  Med Phys       Date:  1992 May-Jun       Impact factor: 4.071

8.  Dose calculation for photon-emitting brachytherapy sources with average energy higher than 50 keV: report of the AAPM and ESTRO.

Authors:  Jose Perez-Calatayud; Facundo Ballester; Rupak K Das; Larry A Dewerd; Geoffrey S Ibbott; Ali S Meigooni; Zoubir Ouhib; Mark J Rivard; Ron S Sloboda; Jeffrey F Williamson
Journal:  Med Phys       Date:  2012-05       Impact factor: 4.071

9.  Lung cancer resection: the prediction of postsurgical outcomes should include long-term functional results.

Authors:  M Beccaria; A Corsico; P Fulgoni; M C Zoia; L Casali; G Orlandoni; I Cerveri
Journal:  Chest       Date:  2001-07       Impact factor: 9.410

10.  Comparison between sublobar resection and 125Iodine brachytherapy after sublobar resection in high-risk patients with Stage I non-small-cell lung cancer.

Authors:  Ricardo Santos; Athanasios Colonias; David Parda; Mark Trombetta; Richard H Maley; Robin Macherey; Susan Bartley; Tibetha Santucci; Robert J Keenan; Rodney J Landreneau
Journal:  Surgery       Date:  2003-10       Impact factor: 3.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.